GLP-1 Drugs Cut Substance-Related Deaths 50%, Study Finds
Updated
Updated · The San Diego Union-Tribune · May 26
GLP-1 Drugs Cut Substance-Related Deaths 50%, Study Finds
5 articles · Updated · The San Diego Union-Tribune · May 26
BMJ-published research from Washington University linked GLP-1 drug use to 50% fewer substance-related deaths, 39% fewer overdoses and 26% fewer drug-related hospitalizations.
Researchers said the drugs appear to dampen reward triggers in the brain, reducing addictive cravings tied to drugs, alcohol and food.
The findings add a potential addiction-related benefit to medicines such as Ozempic and Wegovy, which have been used for diabetes for more than 20 years and for weight loss since 2014.
Long-term use still carries known risks including gastrointestinal problems, kidney issues and vision changes, and researchers said more study is needed.
GLP-1s curb addiction but cause rebound weight gain. Are we trading one dependency for another?
A new pill may prevent weight regain after stopping Ozempic. How soon could this game-changer arrive?
Can a genetic test soon predict if weight loss drugs will work or just cause severe side effects?
GLP-1 Medications Linked to Major Reductions in Substance Use Disorders: Mechanisms, Barriers, and the Future of Addiction Treatment (2026 Report)
Overview
Recent research shows that GLP-1 receptor agonists, medications already used for diabetes, are now linked to significant reductions in substance use disorders (SUDs), including fewer drug-related deaths. This breakthrough could transform addiction treatment by not only improving health outcomes but also reducing the stigma of using medication for SUDs, since GLP-1s are already widely accepted for other conditions. Integrating these medications into SUD protocols offers hope for better acceptance and more people seeking help, marking a major step forward in both medical and social aspects of addiction care.